Format

Send to:

Choose Destination
See comment in PubMed Commons below
Eukaryot Cell. 2009 Apr;8(4):483-6. doi: 10.1128/EC.00298-08. Epub 2009 Jan 23.

Towards new antifolates targeting eukaryotic opportunistic infections.

Author information

  • 1Department of Pharmaceutical Sciences, University of Connecticut, Storrs, CT 06269, USA.

Abstract

Trimethoprim, an antifolate commonly prescribed in combination with sulfamethoxazole, potently inhibits several prokaryotic species of dihydrofolate reductase (DHFR). However, several eukaryotic pathogenic organisms are resistant to trimethoprim, preventing its effective use as a therapeutic for those infections. We have been building a program to reengineer trimethoprim to more potently and selectively inhibit eukaryotic species of DHFR as a viable strategy for new drug discovery targeting several opportunistic pathogens. We have developed a series of compounds that exhibit potent and selective inhibition of DHFR from the parasitic protozoa Cryptosporidium and Toxoplasma as well as the fungus Candida glabrata. A comparison of the structures of DHFR from the fungal species Candida glabrata and Pneumocystis suggests that the compounds may also potently inhibit Pneumocystis DHFR.

PMID:
19168759
[PubMed - indexed for MEDLINE]
PMCID:
PMC2669212
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk